|
First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma. |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck; Merck Serono; Pfizer |
Research Funding - Amgen; Bayer; Boehringer Ingelheim; Genentech; Lilly; Roche |
|
|
Stock and Other Ownership Interests - Calithera Biosciences |
Honoraria - RMEI Medical Education |
Consulting or Advisory Role - Health Advances |
Research Funding - Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Merck |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Merck Sharp & Dohme |
Research Funding - Arog (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Pfizer |
Consulting or Advisory Role - Steba Biotech |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Lilly/ImClone; Merck; Pieris Pharmaceuticals; Roche/Genentech; Taiho Pharmaceutical |
|
|
Stock and Other Ownership Interests - Loxo |
Consulting or Advisory Role - Illumina; Intezyne Technologies; Loxo; Pfizer; Vividion Therapeutics |
Travel, Accommodations, Expenses - Merck KGaA |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Axiom Biotechnologies; Navigant Consulting |
|